Your browser doesn't support javascript.
loading
A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib.
Suzuki, Issei; Kijima, Toshiki; Takada-Owada, Atsuko; Nakamura, Gaku; Uematsu, Toshitaka; Sakamoto, Kazumasa; Nishihara, Daisaku; Ishida, Kazuyuki; Kamai, Takao.
Afiliación
  • Suzuki I; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Kijima T; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Takada-Owada A; Department of Diagnostic Pathology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Nakamura G; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Uematsu T; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Sakamoto K; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Nishihara D; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Ishida K; Department of Diagnostic Pathology Dokkyo Medical University Shimotsuga Tochigi Japan.
  • Kamai T; Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
IJU Case Rep ; 4(6): 412-416, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34755071
ABSTRACT

INTRODUCTION:

We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION A 50-year-old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left-sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8+ T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence-free without any additional treatment for eight months.

CONCLUSION:

For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IJU Case Rep Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IJU Case Rep Año: 2021 Tipo del documento: Article